CytomX/$CTMX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CytomX
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Ticker
$CTMX
Sector
Primary listing
Employees
69
Headquarters
Website
CytomX Metrics
BasicAdvanced
$762m
-
-$0.39
-
-
Price and volume
Market cap
$762m
52-week high
$8.21
52-week low
$1.72
Average daily volume
3.8m
Financial strength
Current ratio
10.378
Quick ratio
10.209
Total debt to equity
0.893
Profitability
EBITDA (TTM)
-60.615
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-166.40%
Operating margin (TTM)
-174.04%
Effective tax rate (TTM)
-0.40%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-16.89%
Return on equity (TTM)
-34.29%
Valuation
Price to revenue (TTM)
15.803
Price to book
2.38
Price to tangible book (TTM)
2.39
Price to free cash flow (TTM)
-7.004
Free cash flow yield (TTM)
-14.28%
Free cash flow per share (TTM)
-0.5
Growth
Revenue change (TTM)
-75.91%
Earnings per share change (TTM)
-179.78%
3-year revenue growth (CAGR)
-19.30%
10-year revenue growth (CAGR)
15.81%
3-year earnings per share growth (CAGR)
-28.76%
10-year earnings per share growth (CAGR)
-18.26%
What the Analysts think about CytomX
Analyst ratings (Buy, Hold, Sell) for CytomX stock.
CytomX Financial Performance
Revenues and expenses
CytomX Earnings Performance
Company profitability
CytomX News
AllArticlesVideos
Why Is CytomX Therapeutics Stock Falling On Wednesday?
Benzinga·2 months ago
Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally
Benzinga·2 months ago
CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CytomX stock?
CytomX (CTMX) has a market cap of $762M as of May 19, 2026.
What is the P/E ratio for CytomX stock?
The price to earnings (P/E) ratio for CytomX (CTMX) stock is 0 as of May 19, 2026.
Does CytomX stock pay dividends?
No, CytomX (CTMX) stock does not pay dividends to its shareholders as of May 19, 2026.
When is the next CytomX dividend payment date?
CytomX (CTMX) stock does not pay dividends to its shareholders.
What is the beta indicator for CytomX?
CytomX (CTMX) does not currently have a Beta indicator.